Showing 5901-5910 of 7127 results for "".
- Mustela Introduces Skin-Soothing PJs for Eczema-Prone Babies and Toddlershttps://practicaldermatology.com/news/mustela-introduces-skin-soothing-pjs-for-eczema-prone-babies-and-toddlers/2459885/The Global Wellness Institute recently cited smart and healing fashion as one of the biggest trends in wellness, and the new Mustela
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson
- Todd Wood Named DermTech's New Chief Commercial Officerhttps://practicaldermatology.com/news/todd-wood-named-dermtechs-new-chief-commercial-officer/2459883/Todd Wood is DermTech’s new Chief Commercial Officer. Mr. Wood will oversee the Sales and Marketing functions. With 25 years of pharmaceutical and medical device commercialization experience, Mr. Wood has launched multiple market leading product
- Cutera to Unveil excel V+ Next Generation Laser Platform at AAD Annual Meetinghttps://practicaldermatology.com/news/cutera-to-unveil-excel-v-next-generation-laser-platform-at-aad-annual-meeting/2459888/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. Cutera will unveil the exce
- Sentient Lasers Unveils Dot Demo Servicehttps://practicaldermatology.com/news/sentient-lasers-unveils-dot-demo-service/2459886/Sentient Lasers has launched its new,
- TARGET PharmaSolutions Launches Real-World Study to Advance the Understanding of AD and Other IMISCshttps://practicaldermatology.com/news/target-pharmasolutions-launches-target-derm-real-world-study-to-advance-the-understanding-of-atopic-dermatitis-and-other-immune-mediated-inflammatory/2459890/TARGET PharmaSolutions, Inc., has launched its latest large-scale observational study, TARGET-DERM (NCT03661866). The study will deliver real-world evidence for several immune-mediated inflammatory skin conditions (IMISCs), initially focusing on patients with atopic dermatitis. TARGET-DERM&
- Physician Burnout Rates Fall Modestlyhttps://practicaldermatology.com/news/physician-burnout-rates-fall-modestly/2459892/The burnout rate among physicians in the United States has dropped, but there remains significant room for improvement, new data suggest. The burnout rate dropped modestly in 2017 from its peak in 2014. Current burnout rates are in line with 2011 levels. The triennial s
- Crown Laboratories Redesigns Blue Lizard Australian Sunscreen Line to Comply with Reef-Safe Legislationhttps://practicaldermatology.com/news/crown-laboratories-launches-redesigned-blue-lizard-australian-sunscreen-line/2459893/Crown Laboratories, Inc., has relaunched its redesigned, dermatologist-recommended Blue Lizard Australian Sunscreen. The company says the redesign includes new products, improved formulations, and a new aesthetic design concept across the entire portfolio based on a year of research to build on t
- FDA Proposes Policy for New Competitive Generic Therapies Pathwayhttps://practicaldermatology.com/news/fda-proposes-policy-for-new-competitive-generic-therapies-pathway/2459896/The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs) creates a designation that can be granted to a company submitting an application for their
- Study Shows 97% Cure Rate for Superficial Radiation Therapy for BCC and SCChttps://practicaldermatology.com/news/study-shows-97-cure-rate-for-superficial-radiation-therapy-for-bcc-and-scc/2459900/A new retrospective study shows a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC) on their lower extremities with SRT-100TM Superficial Radiation Therapy from Sensus Hea